PharmaCielo Ltd.
PCLOF
$0.02
$0.00-3.31%
OTC PK
| 09/30/2025 | 06/30/2025 | 09/30/2024 | 09/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -33.75% | -59.30% | 271.59% | 271.59% | -69.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -33.75% | -59.30% | 271.59% | 271.59% | -69.36% |
| Cost of Revenue | 43.36% | -25.52% | 34.32% | 34.32% | -34.60% |
| Gross Profit | -232.28% | -121.86% | 204.73% | 204.73% | -106.71% |
| SG&A Expenses | 72.60% | -56.85% | -36.23% | -36.23% | -55.46% |
| Depreciation & Amortization | 1.15% | -60.81% | -42.41% | -42.41% | 5.78% |
| Other Operating Expenses | -26.04% | -703.75% | 9.25% | 9.25% | 87.92% |
| Total Operating Expenses | 59.11% | -57.23% | -18.12% | -18.12% | -48.59% |
| Operating Income | -200.58% | 56.25% | 62.57% | 62.57% | 43.28% |
| Income Before Tax | 48.09% | 50.03% | 5.83% | 5.83% | 31.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 48.09% | 50.03% | 5.83% | 5.83% | 31.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.09% | 50.03% | 5.83% | 5.83% | 31.79% |
| EBIT | -200.58% | 56.25% | 62.57% | 62.57% | 43.28% |
| EBITDA | -307.51% | 46.34% | 57.59% | 68.31% | 39.81% |
| EPS Basic | 52.63% | 54.95% | 5.51% | 10.24% | 37.65% |
| Normalized Basic EPS | -108.00% | 55.07% | 34.18% | 36.71% | 36.45% |
| EPS Diluted | 52.63% | 54.95% | 5.51% | 10.24% | 37.65% |
| Normalized Diluted EPS | -108.00% | 55.07% | 34.18% | 36.71% | 36.45% |
| Average Basic Shares Outstanding | 10.74% | 10.74% | 0.00% | 4.76% | 9.14% |
| Average Diluted Shares Outstanding | 10.74% | 10.74% | 0.00% | 4.76% | 9.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |